---
company: BECTON DICKINSON & CO
ticker: BDX
form: 8-K
filed: 2026-11-05
accepted: 2026-11-05T11:31:38+00:00
accession: 0001628280-26-070511
source: https://www.sec.gov/Archives/edgar/data/10795/000162828026070511/
---

# Becton Dickinson (BDX) Q4 2026 earnings

## Header

- Company: Becton Dickinson & Co
- Reported: 2026-11-05 06:31 BMO ET
- Source: 8-K only — accession 0001628280-26-070511, Item 2.02 + Exhibit 99.1
- Verdict: Revenue grew 5% year-over-year, but adjusted EPS declined 2% due to a 1.2 percentage-point compression in adjusted EBITDA margin.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $10.26B | +5% | +2% | Ex. 99.1, Income Statement |
| EPS (GAAP) | $1.85 | +2% | +1% | Ex. 99.1, Income Statement |
| EPS (adjusted) | $2.20 | -2% | +1% | Ex. 99.1, Income Statement |
| Net income | $1.30B | +3% | +2% | Ex. 99.1, Income Statement |
| Adj. EBITDA | $2.44B | +2% | +1% | Ex. 99.1, Income Statement |
| Adj. EBITDA margin | 23.8% | -1.2 pp | +0.3 pp | Ex. 99.1, Income Statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Medical - Surgical | $3.20B | +4% | 31% | Strong performance in U.S. and international markets |
| Interventional | $2.10B | +6% | 20% | Solid growth in catheters and guidewires |
| Diabetes Care | $2.50B | +3% | 24% | Steady demand for insulin delivery systems |
| MedTech | $2.46B | +7% | 24% | Growth in respiratory and vascular products |

## Margins and costs

- Gross margin: 67.6% (prior 67.8%, change -0.2 pp)
- Operating expenses: $3.04B (+4% YoY)
- One-offs in the quarter: Tax rate impact: 16.5% (vs 18.0% prior year); Restructuring charges: $8M
- Effective tax rate: 16.5% (prior-year 18.0%, year-to-date 17.2%)
- Non-GAAP bridge: Adds back stock-based compensation ($312M), amortization of intangibles ($115M), and acquisition-related costs ($45M).

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Free cash flow | $1.85B | $1.70B | $1.80B | +9% |
| Revenue backlog | $12.5B | $12.0B | $11.8B | +4% |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---:|
| Revenue | $10.5B - $10.7B | $10.4B - $10.6B | +0.1 pp |
| Adjusted EPS | $2.15 - $2.25 | $2.20 - $2.30 | -0.05 pp |

## What drove it

- Revenue story: Revenue increased 5% year-over-year, driven by strength in MedTech (+7%) and Interventional (+6%), partially offset by a 3% decline in Diabetes Care.
- EPS story: Adjusted EPS declined 2% year-over-year, primarily due to a 1.2 percentage-point compression in adjusted EBITDA margin and higher operating expenses (+4%).
- One-off check: Restructuring charges of $8M and a lower tax rate of 16.5% (vs 18.0% prior year) impacted the quarter.

## The good

- Revenue backlog grew 4% to $12.5B
- Free cash flow increased 9% to $1.85B

## The bad

- Adjusted EPS declined 2% year-over-year
- Adjusted EBITDA margin compressed 1.2 pp

## The ugly

- none

## Open questions

- The release does not quantify the specific impact of the lower tax rate on net income.
- The release does not disclose the specific drivers of the 3% decline in Diabetes Care revenue.

## Full release

### Becton Dickinson (BDX) earnings release, November 5, 2026

Becton Dickinson & Co (BDX) · Form 8-K, Item 2.02 · Filed 2026-11-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/10795/000162828026070511/)

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 ex9919302026.htm Additional exhibits
